Category
Pazopanib
CAS Number
1821666-71-0
Molecular Formula
C14H16N6
Molecular Weight
268.3 g/mol
Synonym

N4-(2,3-Dimethyl-2H-indazol-6-yl)-N4-methylpyrimidine-2,4-diamine;4-N-(2,3-dimethylindazol-6-yl)-4-N-methylpyrimidine-2,4-diamine;

Keywords
Impurities
Metabolites.
Pharmaceutical Standards
Fine Chemicals
Slide_1
Purity:

Above - 95.0%

Technical Data:

We will provide complete documentation support for every Standard Material. All analytical reports such as ¹H NMR, ¹³C NMR, Mass, FT-IR, HPLC Purity/GC Purity/QNMR Purity, Water content by KF/ Loss on Drying/TGA (Thermo-gravimetric Analysis). Certificate of Analysis with potency report. Each Standard Material SER (Structure Elucidation Report) with NMR, Mass, IR spectral interpretation. This whole analytical document can be included in eCTD, ANDA, DMF submissions to regulatory agencies.

Pazopanib Impurity 17 is a recognized process-related impurity of the anticancer drug pazopanib, chemically known as N4-(2,3-dimethyl-2H-indazol-6-yl)-N4-methylpyrimidine-2,4-diamine, and is used as a reference standard in pharmaceutical quality control to support analytical method development, validation, and impurity profiling, ensuring the safety, efficacy, and purity of the final drug product.